Migdal Insurance & Financial Holdings Ltd. Allogene Therapeutics, Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$7.12 Billion
Q1 2025

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 04, 2021	SELL	$23.49 - $35.8 $493,172 - $751,620	-20,995 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$25.79 - $39.02 $541,461 - $819,224	20,995 New	20,995 $741,000

Others Institutions Holding ALLO

# of Institutions

176

Shares Held

165M

Call Options Held

202K

Put Options Held

76.6K

Tpg Gp A, LLC Fort Worth, TX

18.7M
Shares

$21.7 Million
0.84% of portfolio
Black Rock Inc. New York, NY

16.4M
Shares

$19.1 Million
0.0% of portfolio
Capital World Investors Los Angeles, CA

12.3M
Shares

$14.2 Million
0.0% of portfolio
Lynx1 Capital Management LP San Juan, PR

11.1M
Shares

$12.8 Million
5.97% of portfolio
Darwin Global Management, Ltd. St. Helier, Y9

10.4M
Shares

$12.1 Million
1.06% of portfolio

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $167M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account